Morgan Stanley Downgrades IMS Health (RX) to Underweight
More News related to RX
- IMS Names Kimberly Gray Chief Privacy Officer, Americas
- IMS to Present at the William Blair Growth Stock Conference on June 10 at 2:00 p.m. CT
- IMS to Present at Goldman Sachs Global Healthcare Conference on June 9 at 3:45 p.m. ET
- BioSyent Releases 2009 First Quarter Financial Results
- BioSyent Releases 2009 First Quarter Financial Results
Morgan Stanley downgrades IMS Health (NYSE: RX) from Equalweight to Underweight. Price target $18.
IMS Health Incorporated (IMS) is a provider of market intelligence to the pharmaceutical and healthcare industries.
Related Categories
DowngradesStocks Mentioned
+13.50Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
